These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 27636993)

  • 1. T4/N2 classification nasopharyngeal carcinoma benefit from concurrent chemotherapy in the era of intensity-modulated radiotherapy.
    Xie R; Xia B; Zhang X; Hu W; Zhao R; Xie C; Wang J; Zhang N; Wu S
    Oncotarget; 2016 Dec; 7(49):81918-81925. PubMed ID: 27636993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
    Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
    Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study.
    Zhang WW; Lin JY; Wang GY; Huang CL; Tang LL; Mao YP; Zhou GQ; Liu LZ; Tian L; Li JB; Ma J; Guo R
    Radiother Oncol; 2024 May; 194():110189. PubMed ID: 38432309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.
    Zhang LN; Gao YH; Lan XW; Tang J; Su Z; Ma J; Deng W; OuYang PY; Xie FY
    Oncotarget; 2015 Dec; 6(41):44019-29. PubMed ID: 26528755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
    Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
    Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities.
    Sun X; Su S; Chen C; Han F; Zhao C; Xiao W; Deng X; Huang S; Lin C; Lu T
    Radiother Oncol; 2014 Mar; 110(3):398-403. PubMed ID: 24231245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study.
    Lin Q; Lu L; Wang X; Lin Y; Chen Y; Chen H; Chen S; Lin S; Zhang Y; Zheng P; Chen X
    Am J Otolaryngol; 2022; 43(1):103193. PubMed ID: 34509080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of adaptive replanning in patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: a propensity score matched analysis.
    Luo Y; Qin Y; Lang J
    Clin Transl Oncol; 2017 Apr; 19(4):470-476. PubMed ID: 27718153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study.
    Liu DH; Zhou XY; Pan YG; Chen S; Ye ZH; Chen GD
    Cancer Med; 2020 Feb; 9(4):1287-1297. PubMed ID: 31859464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
    Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
    Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of advanced nasopharyngeal cancer using low- or high-dose concurrent chemoradiotherapy with intensity-modulated radiotherapy: A propensity score-matched, nationwide, population-based cohort study.
    Chen TM; Lin KC; Yuan KS; Chang CL; Chow JM; Wu SY
    Radiother Oncol; 2018 Oct; 129(1):23-29. PubMed ID: 29277447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma.
    Aftab O; Liao S; Zhang R; Tang N; Luo M; Zhang B; Shahi S; Rai R; Ali J; Jiang W
    Radiat Oncol; 2020 Mar; 15(1):66. PubMed ID: 32178698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution.
    Fangzheng W; Chuner J; Zhiming Y; Tongxin L; Fengqin Y; Lei W; Bin L; Fujun H; Ming C; Weifeng Q; Zhenfu F
    Oncol Res; 2018 Mar; 26(2):277-287. PubMed ID: 29046165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study.
    Su Z; Mao YP; Tang J; Lan XW; OuYang PY; Xie FY
    Tumour Biol; 2016 Apr; 37(4):4429-38. PubMed ID: 26499947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy alone in nasopharyngeal carcinoma.
    OuYang PY; Shi D; Sun R; Zhu YJ; Xiao Y; Zhang LN; Zhang XH; Chen ZY; Lan XW; Tang J; Gao YH; Ma J; Deng W; Xie FY
    Oncotarget; 2016 May; 7(22):33408-17. PubMed ID: 27058901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent chemoradiotherapy versus radiotherapy alone in older patients with stage II nasopharyngeal carcinoma after intensity-modulated radiotherapy: A propensity score-matched cohort study.
    Wang F; Zhou L; Zhang LJ; Xie CB; Liao ZW; Lin XD; Wen YF
    Radiother Oncol; 2024 Feb; 191():110081. PubMed ID: 38185256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy.
    Hua YJ; Han F; Lu LX; Mai HQ; Guo X; Hong MH; Lu TX; Zhao C
    Eur J Cancer; 2012 Dec; 48(18):3422-8. PubMed ID: 22835782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial.
    Ke LR; Xia WX; Qiu WZ; Huang XJ; Yang J; Yu YH; Liang H; Liu GY; Ye YF; Xiang YQ; Guo X; Lv X
    BMC Cancer; 2017 Feb; 17(1):134. PubMed ID: 28202000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensity-modulated radiation therapy achieves better local control compared to three-dimensional conformal radiation therapy for T4-stage nasopharyngeal carcinoma.
    Chen JL; Huang YS; Kuo SH; Hong RL; Ko JY; Lou PJ; Wang CW
    Oncotarget; 2017 Feb; 8(8):14068-14077. PubMed ID: 27764778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.